InveniAI

InveniAI provides artificial intelligence (AI) drug discovery services to pharmaceutical companies to accelerate drug development by leveraging its AIphaMeld technology, a universal signal detection system that uses AI and machine learning technologies. 

Its AlphaMeld AI platform helps identify alpha signals for targets, drugs, and healthcare products. The company caters to a range of industries, including healthcare, food and nutrition, agri-tech, aviation, chemicals, and government.

The Connecticut-based firm was spun out from its parent company BioXcel LLC in 2017 to focus on AI applications for drug discovery and development. It currently has 3 AI-powered drugs in its pipeline: two new chemical entities (INVA8002 and INVA8003) and one novel combination of approved drugs (INVA8001). An investigational new drug (IND) application is expected to be submitted for INVA8001 in Q4 2021, for INVA8002 in Q2 2022, and INVA8003 in Q4 2022.

The company has multiple drug development collaborations with biopharma and biotech companies and around 10 collaborative drug programs in its pipeline to treat chronic inflammatory diseases. 

In July 2021, InveniAI entered into a collaboration with the Japanese pharmaceutical company Shionogi in April 2021—followed by a multi-target drug discovery collaboration with Sosei Group Corporation, a G-protein coupled receptors (GPCRs)-focused drug discovery company—to generate novel compounds for unmet conditions.